

Supplementary Data

SUPPLEMENTARY TABLE S2. ABBREVIATED INDICATIONS WITH PPR CALCULATED
FOR NEW DRUGS APPROVED BY FDA CDER (2013–2015)

<i>Abbreviated indication</i>	<i>Established name (proprietary name)</i>
1. Acquired generalized lipodystrophy	Metreleptin (Myalept)
2. Acute lymphoblastic leukemia	Blinatumomab (Blincyto)
3. Acute otitis externa	Finafloxacin (Xtoro)
4. Asthma	Mepolizumab (Nucala)
5. Atrial fibrillation	Edoxaban (Savaysa)
6. Basal cell carcinoma	Sonidegib (Odomzo)
7. Bipolar 1 disorder	Cariprazine (Vraylar)
8. Breast cancer	Ado-trastuzumab emtansine (Kadcyla)
9. Chemotherapy-induced nausea and vomiting	Netupitant and palonosetron (Akynzeo)
Chemotherapy-induced nausea and vomiting	Rolapitant (Varubi)
10. Chronic lymphocytic leukemia	Idelalisib (Zydelig)
Chronic lymphocytic leukemia	Obinutuzumab (Gazyva)
11. Chronic obstructive pulmonary disease	Fluticasone furoate and vilanterol trifenate (Breo Ellipta)
Chronic obstructive pulmonary disease	Olodaterol (Striverdi Respimat)
Chronic obstructive pulmonary disease	Umeclidinium bromide and vilanterol trifenate (Anoro Ellipta)
12. Chronic thromboembolic pulmonary hypertension	Riociguat (Adempas)
13. Colorectal cancer	Trifluridine and tipiraci (Lonsurf)
14. Crohn's disease	Vedolizumab (Entyvio)
15. Cystic fibrosis	Lumacaftor/ivacaftor (Orkambi)
16. Diabetes mellitus	Albiglutide (Tanzeum)
Diabetes mellitus	Alogliptin (Nesina)
Diabetes mellitus	Alogliptin/metformin (Kazano)
Diabetes mellitus	Alogliptin/pioglitazone (Oseni)
Diabetes mellitus	Canagliflozin (Invokana)
Diabetes mellitus	Dapagliflozin (Farxiga)
Diabetes mellitus	Dulaglutide (Trulicity)
Diabetes mellitus	Empagliflozin (Jardiance)
Diabetes mellitus	Insulin degludec (Tresiba)
Diabetes mellitus	Insulin degludec/insulin aspart (Ryzodeg)
17. Follicular B cell non-Hodgkin lymphoma	Idelalisib (Zydelig)
18. Gastric cancer	Ramucirumab (Cyramza)
19. Gastroesophageal junction adenocarcinoma	Ramucirumab (Cyramza)
20. Gaucher disease type 1	Eliglustat (Cerdelga)
21. Gout	Lesinurad (Zurampic)
22. Heart failure	Ivabradine (Corlanor)
Heart failure	Sacubitril and valsartan (Entresto)
23. Hepatitis C virus, chronic	Daclatasvir (Daklinza)
Hepatitis C virus, chronic	Ledipasvir and sofosbuvir (Harvoni)
Hepatitis C virus, chronic	Ombitasvir, paritaprevir, ritonavir, and dasabuvir (Viekira Pak)
Hepatitis C virus, chronic	Simeprevir (Olysio)
Hepatitis C virus, chronic	Sofosbuvir (Sovaldi)
24. Human immunodeficiency virus	Dolutegravir (Tivicay)
Human immunodeficiency virus	Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya)
25. Idiopathic pulmonary fibrosis	Nintedanib (Ofev)
Idiopathic pulmonary fibrosis	Pirfenidone (Esbriet)
26. Influenza	Peramivir (Rapivab)
27. Insomnia	Suvorexant (Belsomra)
28. Intra-abdominal infections, complicated	Ceftazidime-avibactam (Avycaz)
Intra-abdominal infections, complicated	Ceftolozane/tazobactam (Zerbaxa)
29. Invasive aspergillosis	Isavuconazonium sulfate (Cresemba)
30. Irritable bowel syndrome with diarrhea	Eluxadoline (Viberzi)

(continued)

SUPPLEMENTARY TABLE S2. (CONTINUED)

<i>Abbreviated indication</i>	<i>Established name (proprietary name)</i>
31. Leiomyosarcoma	Trabectedin (Yondelis)
32. Liposarcoma	Trabectedin (Yondelis)
33. Major depressive disorder	Brexpiprazole (Rexulti)
Major depressive disorder	Vortioxetine (Brintellix)
34. Mantle cell lymphoma	Ibrutinib (Imbruvica)
35. Melanoma	Nivolumab (Opdivo)
Melanoma	Pembrolizumab (Keytruda)
36. Melanoma– <i>BRAF V600E</i>	Cobimetinib (Cotellic)
Melanoma– <i>BRAF V600E</i>	Dabrafenib (Tafinlar)
Melanoma– <i>BRAF V600E</i>	Trametinib (Mekinist)
37. Melanoma– <i>BRAF V600K</i>	Cobimetinib (Cotellic)
Melanoma– <i>BRAF V600K</i>	Trametinib (Mekinist)
38. Mucopolysaccharidosis type IVA (Morquio A syndrome)	Elosulfase alfa (Vimizim)
39. Multicentric Castleman's disease	Siltuximab (Sylvant)
40. Multiple myeloma	Daratumumab (Darzalex)
Multiple myeloma	Elotuzumab (Empliciti)
Multiple myeloma	Ixazomib (Ninlaro)
Multiple myeloma	Panobinostat (Farydak)
Multiple myeloma	Pomalidomide (Pomalyst)
41. Multiple sclerosis	Dimethyl fumarate (Tecfidera)
Multiple sclerosis	Peginterferon beta-1a (Plegridy)
42. Noncancer pain, chronic	Naloxegol (Movantik)
43. Nonsmall cell lung cancer	Afatinib (Gilotrif)
Nonsmall cell lung cancer	Necitumumab (Portrazza)
44. NSCLC– <i>ALK+</i>	Alectinib (Alecensa)
NSCLC– <i>ALK+</i>	Ceritinib (Zykadia)
45. NSCLC– <i>EGFR T790M</i>	Osimertinib (Tagrisso)
46. Onychomycosis	Efinaconazole (Jublia)
Onychomycosis	Tavaborole (Kerydin)
47. Percutaneous coronary intervention	Cangrelor (Kengreal)
48. Peripheral T cell lymphoma	Belinostat (Beleodaq)
49. Plaque psoriasis	Secukinumab (Cosentyx)
50. Psoriatic arthritis, active	Apremilast (Otezla)
51. Pulmonary arterial hypertension	Macitentan (Opsumit)
Pulmonary arterial hypertension	Riociguat (Adempas)
Pulmonary arterial hypertension	Selexipag (Upravi)
52. Schizophrenia	Aripiprazole lauroxil (Aristada)
Schizophrenia	Brexpiprazole (Rexulti)
Schizophrenia	Cariprazine (Vraylar)
53. Small lymphocytic lymphoma	Idelalisib (Zydelig)
54. Submental fat	Deoxycholic acid (Kybella)
55. Thyroid cancer	Lenvatinib (Lenvima)
56. Tinea corporis	Luliconazole (Luzu)
57. Tinea cruris	Luliconazole (Luzu)
58. Tinea pedis	Luliconazole (Luzu)
59. Ulcerative colitis	Vedolizumab (Entyvio)
60. Venous thromboembolism	Edoxaban (Savaysa)

ALK+, anaplastic lymphoma kinase-positive; CDER, Center for Drug Evaluation and Research; *EGFR*, epidermal growth factor receptor; FDA, Food and Drug Administration; NSCLC, nonsmall cell lung cancer.